PRSS30P

Across TCGA pan-cancer cohorts, PRSS30P RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PRSS30P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where PRSS30P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRSS30P is over-expressed in tumor, although a few such as UCEC and KICH show the opposite, repressed pattern.

KIRC, COAD, and UCEC are the cancer types where PRSS30P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRSS30P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.422	<.001	11	view →
COAD	Female	All	+0.857	<.001	8	view →
UCEC	All	All	−0.714	<.001	6	view →
KICH	Male	All	−0.361	<.001	6	view →
STAD	All	All	+0.341	<.001	4	view →
BRCA	All	All	+0.209	.003	4	view →
CHOL	Female	All	+0.496	.006	3	view →
LUSC	Female	II,III,IV	−0.452	<.001	3	view →
READ	All	All	+0.550	.004	2	view →
LIHC	All	All	+0.112	.018	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PRSS30P–KIRC

Open the KIRC breakdown →